Peptide Research

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Its mechanisms of action are multifaceted and have been studied extensively in over 100 animal studies. A central aspect of its activity involves upregulation of growth factor expression, including VEGF (vascular endothelial growth factor), EGF (epidermal growth factor), and their receptors. This pro-angiogenic activity helps explain its remarkable wound-healing and tissue-repair properties observed across multiple tissue types.

BPC-157 also interacts with the nitric oxide (NO) system in a complex, context-dependent manner. It can rescue NO production when it is pathologically inhibited and can attenuate excessive NO when it is overproduced, suggesting a modulatory rather than unidirectional effect. Research by Sikiric et al. has demonstrated that BPC-157 interacts with the dopaminergic system and may counteract both the acute and chronic effects of dopaminergic agents, pointing to direct CNS activity.

At the gastrointestinal level, BPC-157 maintains mucosal integrity by promoting granulation tissue formation and angiogenesis within lesion sites. It has shown cytoprotective effects against NSAID-induced gastric damage, ethanol-induced lesions, and stress ulcers in numerous rodent models. The peptide appears to modulate the FAK-paxillin pathway, which is critical for cell migration and adhesion during wound repair.

Thymosin beta-4 (Tbeta4) is a 43-amino-acid peptide that is the most abundant member of the beta-thymosin family. Despite its name (a historical artifact from its original isolation from thymus tissue), Tbeta4 is expressed in virtually all nucleated cells and is one of the most abundant intracellular peptides, with concentrations reaching 0.4 mM in some cell types. TB-500 is a synthetic version commonly used in research.

The primary intracellular function of Tbeta4 is sequestration of G-actin (globular, monomeric actin), regulating the pool of actin available for polymerization into F-actin (filamentous actin). This function is critical because actin polymerization drives cell migration — a rate-limiting step in wound healing. By maintaining a reserve of polymerization-ready G-actin, Tbeta4 enables rapid cell migration when needed. The active site responsible for actin binding is the central region containing the sequence LKKTET.

Beyond actin regulation, Tbeta4 has potent anti-inflammatory activity. It suppresses NF-kB signaling and reduces pro-inflammatory cytokine expression. Bock-Marquette et al. made a landmark discovery showing Tbeta4 activates Akt (protein kinase B) in cardiomyocytes, promoting survival after ischemic injury. This finding opened research into cardiac repair applications. Tbeta4 also promotes angiogenesis, hair follicle stem cell migration, and has been shown to reduce corneal inflammation and scarring.

The Wolverine Blend combines the two most extensively studied tissue-repair peptides in complementary research: BPC-157 and TB-500 (thymosin beta-4). The blend name references the fictional character's regenerative abilities, reflecting the synergistic healing potential suggested by the combined research profiles of these peptides.

BPC-157 acts primarily through pro-angiogenic mechanisms — it upregulates VEGF, EGF, and their receptors to promote new blood vessel formation at injury sites. It also modulates the nitric oxide system and the FAK-paxillin pathway critical for cell adhesion and migration during wound repair. Its effects have been demonstrated across tendon, ligament, muscle, bone, skin, and gastrointestinal tissues in over 100 animal studies.

TB-500 acts through a complementary mechanism centered on actin biology. By sequestering G-actin monomers, TB-500 regulates the pool of actin available for polymerization, which directly controls cell migration speed. Since cell migration into wound beds is often the rate-limiting step in tissue repair, TB-500 effectively removes this bottleneck. It additionally provides anti-inflammatory activity through NF-kB suppression and promotes cardiomyocyte survival through Akt activation.

The rationale for combining these peptides is that they address different stages and requirements of the healing cascade: BPC-157 establishes the vascular supply needed for repair, while TB-500 accelerates the cellular migration that populates the repair site. Together, they create conditions for faster, more complete tissue regeneration than either alone.

CJC-1295 without DAC, also known as Modified GRF(1-29), is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH) with four amino acid substitutions designed to improve metabolic stability. The modifications (Ala at position 2 to D-Ala, Asn at position 8 to Gln, Ala at position 15 to Ala (retained), and Met at position 27 to Leu) confer resistance to DPP-4 and other proteolytic enzymes while preserving full GHRH receptor binding affinity.

The 'without DAC' designation distinguishes it from CJC-1295 with DAC (Drug Affinity Complex), which includes a maleimidopropionic acid linker that enables covalent binding to serum albumin. Without the DAC modification, this version has a shorter half-life of approximately 30 minutes, producing a more physiological acute GH pulse rather than the sustained GH elevation seen with the DAC version.

CJC-1295 without DAC binds GHRH receptors on pituitary somatotrophs and activates the Gs-cAMP-PKA pathway to stimulate GH release. Its shorter-acting nature produces GH pulses that more closely mimic natural secretion patterns, which some researchers prefer for maintaining physiological feedback regulation. It is frequently studied in combination with ghrelin receptor agonists like ipamorelin for synergistic GH release.

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts as a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a). Unlike earlier GHS compounds such as GHRP-6 and GHRP-2, ipamorelin is notable for its high selectivity — it stimulates growth hormone release without significantly affecting cortisol, prolactin, or ACTH levels at GH-stimulating doses. This selectivity was first characterized by Raun and colleagues at Novo Nordisk in 1998.

Ipamorelin binds GHS-R1a on pituitary somatotroph cells, triggering intracellular calcium influx via phospholipase C and IP3 pathways. This calcium mobilization causes GH-containing granule fusion with the cell membrane and GH exocytosis. The peptide produces dose-dependent GH release with a well-defined dose-response curve and a ceiling effect, meaning higher doses do not produce proportionally greater GH release — a property that contributes to its safety profile.

Research has also explored ipamorelin's effects on gastrointestinal motility. Hansen et al. demonstrated that ipamorelin accelerates gastric emptying and colonic transit time in post-operative ileus models, leading to investigation as a potential prokinetic agent. This GI activity is mediated through ghrelin receptor activation in the enteric nervous system.

Tesamorelin is a synthetic analogue of human GHRH (growth hormone-releasing hormone) comprising all 44 amino acids of native GHRH with an added trans-3-hexenoic acid moiety at the N-terminus. This modification enhances resistance to DPP-4 enzymatic degradation without altering receptor binding affinity, resulting in improved bioavailability compared to native GHRH. Tesamorelin is FDA-approved under the brand name Egrifta for the treatment of excess visceral abdominal fat in HIV-infected patients with lipodystrophy.

Tesamorelin binds to GHRH receptors on anterior pituitary somatotrophs, stimulating GH synthesis and secretion through the cAMP/PKA signaling cascade. Like sermorelin, it promotes physiological pulsatile GH release while preserving somatostatin-mediated feedback regulation. The resulting GH elevation stimulates hepatic IGF-1 production and downstream metabolic effects including lipolysis, particularly in visceral adipose depots.

Clinical trials demonstrated significant reductions in visceral adipose tissue (VAT) — approximately 15-18% reduction over 26 weeks in HIV lipodystrophy patients. Importantly, tesamorelin reduced VAT without significantly affecting subcutaneous fat, suggesting preferential action on metabolically active visceral depots. Additional research has explored cognitive benefits, with Stanley et al. demonstrating improved executive function and verbal memory in older adults.

AOD-9604 is a modified fragment of human growth hormone (hGH) spanning amino acids 176-191, with an added tyrosine at the N-terminus to enhance stability. It was developed to isolate the lipolytic (fat-burning) activity of growth hormone from its growth-promoting and diabetogenic effects. The peptide stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, and notably does not induce IGF-1 production or affect blood glucose homeostasis.

The mechanism appears to involve activation of beta-3 adrenergic receptor-related pathways in adipose tissue. Research by Ng and colleagues demonstrated that AOD-9604 mimics the way natural growth hormone regulates fat metabolism — it stimulates the breakdown of stored triglycerides in adipocytes while simultaneously blocking the formation of new fat. Importantly, studies have confirmed it does not compete with hGH for receptor binding, suggesting it acts through an independent signaling pathway.

More recent research has explored AOD-9604's effects on cartilage. Studies have shown it may promote proteoglycan and collagen synthesis in chondrocytes, opening potential applications in osteoarthritis research beyond its original anti-obesity focus.

MOTS-c is a 16-amino-acid peptide encoded by the mitochondrial genome within the 12S rRNA gene. Discovered by Changhan David Lee and Pinchas Cohen at the University of Southern California in 2015, it was one of the first mitochondrial-derived peptides (MDPs) identified with significant metabolic regulatory activity. Its discovery challenged the longstanding view that the mitochondrial genome encodes only 13 proteins, 22 tRNAs, and 2 rRNAs.

MOTS-c's primary mechanism involves activation of the AMPK (AMP-activated protein kinase) pathway, the master cellular energy sensor. It inhibits the folate cycle and de novo purine biosynthesis, leading to accumulation of AICAR (an endogenous AMPK activator). This AMPK activation promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis — effects that closely mimic the metabolic benefits of exercise. Lee et al. showed that MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance in mice.

Remarkably, MOTS-c can translocate to the nucleus during metabolic stress, where it regulates nuclear gene expression through interaction with the antioxidant response element (ARE). This represents a novel form of mitochondrial-nuclear communication (retrograde signaling). MOTS-c levels decline with age in human plasma, and exercise has been shown to acutely increase circulating MOTS-c levels, linking it to the molecular mechanisms underlying exercise benefits.

Selank 11mg contains the same selank heptapeptide as the 10mg product — a synthetic derivative of tuftsin with anxiolytic, nootropic, and immunomodulatory properties. The mechanism involves GABA-A receptor modulation, enkephalin-degrading enzyme inhibition, and BDNF expression enhancement. See the Selank 10mg entry for comprehensive research details.

The 11mg vial provides slightly more material than the 10mg version, offering flexibility for research protocols that require marginally larger quantities per vial.

Semax is a synthetic heptapeptide based on ACTH(4-7) (the fragment Met-Glu-His-Phe from adrenocorticotropic hormone) with an added Pro-Gly-Pro C-terminal extension for metabolic stability. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences alongside selank, semax is approved in Russia as a nootropic and neuroprotective medication.

Semax does not activate the melanocortin receptors associated with full-length ACTH and does not affect cortisol or adrenal function. Instead, it influences brain function through modulation of neurotrophic factor expression. Research has shown semax significantly upregulates BDNF (brain-derived neurotrophic factor) and its receptor TrkB, as well as NGF (nerve growth factor) in the hippocampus and cortex. These neurotrophins are critical for neuronal survival, synaptic plasticity, and learning.

Semax also modulates monoaminergic neurotransmission. It influences dopaminergic and serotonergic systems in the brain, which may contribute to its cognitive-enhancing and antidepressant-like effects observed in behavioral studies. In stroke research, semax has shown neuroprotective effects when administered during the acute phase of cerebral ischemia, reducing infarct volume and improving functional outcomes in animal models.